Cargando…
The future of cytotoxic therapy: selective cytotoxicity based on biology is the key
Although mortality from breast cancer is decreasing, 15% or more of all patients ultimately develop incurable metastatic disease. It is hoped that new classes of target-based cytotoxic therapeutics will significantly improve the outcome for these patients. Many of these novel agents have displayed c...
Autores principales: | de Bono, Johann S, Tolcher, Anthony W, Rowinsky, Eric K |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC165009/ https://www.ncbi.nlm.nih.gov/pubmed/12793897 |
Ejemplares similares
-
Granzyme B; the chalk-mark of a cytotoxic lymphocyte
por: Waterhouse, Nigel J, et al.
Publicado: (2004) -
Armed and accurate: engineering cytotoxic T cells for eradication of leukemia
por: Radic, Marko
Publicado: (2012) -
Copper Cytotoxicity: Cellular Casualties of Noncognate Coordination Chemistry
por: O’Hern, Charlotte I. Z., et al.
Publicado: (2022) -
Back to the future: evolutionary biology reveals a key regulatory switch in neuroblastoma pathogenesis
por: Wertman, Jaime N., et al.
Publicado: (2023) -
The Future of Smallpox Vaccination: is MVA the key?
por: Slifka, Mark K
Publicado: (2005)